Financial Performance - The company's operating revenue for 2024 was ¥763,793,394.09, a decrease of 16.02% compared to ¥909,506,771.72 in 2023[6]. - Net profit attributable to shareholders for 2024 was ¥36,403,379.34, down 38.05% from ¥58,767,086.78 in 2023[6]. - The cash flow from operating activities for 2024 was ¥91,509,751.31, representing a decline of 29.20% from ¥129,246,864.39 in 2023[6]. - Basic earnings per share for 2024 were ¥0.06, a decrease of 40.00% compared to ¥0.10 in 2023[6]. - Total assets at the end of 2024 were ¥985,730,497.97, down 13.89% from ¥1,144,706,388.58 at the end of 2023[6]. - The company reported a significant increase in cash outflows from financing activities, totaling ¥144,650,201.74, a rise of 3,970.53% from ¥3,553,592.40[112]. - The company's total revenue for 2024 was approximately ¥763.79 million, a decrease of 16.02% compared to ¥909.51 million in 2023[97]. - Revenue from cardiovascular system drugs was ¥506.48 million, accounting for 66.31% of total revenue, with a year-on-year decline of 22.56%[97]. - Revenue from musculoskeletal system drugs was ¥186.28 million, a slight decrease of 0.95% year-on-year[57]. - Revenue from antiviral respiratory system drugs increased by 24.88% year-on-year, reaching 22.03 million yuan[57]. Product and Market Overview - The company’s main products include four exclusive medical insurance pillar products, which are critical to its revenue[13]. - The company has a total of 162 drug approval numbers, including 15 exclusive products, with a strong product line centered around four major exclusive medical insurance products[37]. - The four major exclusive medical insurance pillar products include 沃华®心可舒片, 骨疏康胶囊/颗粒, 荷丹片/胶囊, and 脑血疏口服液, with varying insurance classifications[45]. - The company has established strong products in the fields of cardiovascular and skeletal chronic diseases, which are expected to benefit from the dual factors of aging and chronic disease prevalence[30]. - The company recognizes the broad prospects of traditional Chinese medicine, leveraging its unique advantages in treating chronic diseases[31]. - The total amount of online procurement orders for traditional Chinese medicine reached CNY 206 billion in 2024, accounting for 2,060 billion of the total CNY 9,962 billion in national procurement orders[34]. - The company’s exclusive products are supported by numerous clinical guidelines and consensus documents, with 沃华®心可舒片 having 33 related documents[45]. Research and Development - The company is focusing on modernizing traditional Chinese medicine through continuous research and development, enhancing product competitiveness and quality control[39]. - The company has established a research institute to attract top talent for new product development and patent registration[47]. - The company’s research and development model includes both independent and collaborative efforts, focusing on innovation and optimization[47]. - The company has obtained a national invention patent certificate for "Lysine Phosphate Calcium Granules and its Preparation Method" during the reporting period[50]. - The company is actively involved in the development of new drugs and secondary product development under national policies supporting traditional Chinese medicine[51]. - The company has developed a rapid detection method for the effective components in Xinkeshu Tablets[50]. - The company is investing in R&D, allocating 100 million yuan towards the development of new technologies and products[165]. Compliance and Governance - The company has established a compliance management system, but risks remain from improper commercial practices by downstream clients or employees[137]. - The company maintains a governance structure that complies with relevant laws and regulations, ensuring independent operations from its controlling shareholder[142]. - The company has established a transparent performance evaluation and incentive mechanism for its directors and senior management[149]. - The audit committee reviewed the 2023 annual financial report and audit report, ensuring compliance with regulatory standards[179]. - The company received a warning letter from the Shandong Securities Regulatory Bureau for violations of information disclosure regulations[171]. - The company has implemented a value management system and disclosed plans for enhancing valuation[138]. Marketing and Sales Strategy - The company has enhanced its marketing strategy by emphasizing online academic promotion and expanding coverage through platforms like JD and Douyin[67]. - The company is focusing on enhancing its marketing strategies by integrating professional clinical promotion with digital marketing initiatives[56]. - The marketing system has been enhanced to cover all terminal categories, with a focus on academic promotion and targeted strategies for different market segments[91]. - The company aims to strengthen its marketing platform by leveraging its four proprietary products to drive sales growth across its entire product range[130]. - The company is committed to expanding its online presence through partnerships with major e-commerce platforms, targeting outpatient markets to create new revenue streams[130]. Risk Management - The company faces risks related to the concentration of its main products and potential policy changes affecting drug pricing and market access, necessitating proactive risk management strategies[134]. - The company acknowledges the risk of intensified market competition in the cardiovascular drug sector, which may threaten sales of its leading products[136]. - The company is actively monitoring potential risks related to changes in actual control due to an ongoing legal dispute involving its major shareholder[137]. - Recent fluctuations in raw material prices have led to an increase in manufacturing costs, impacting the company's normal profit levels[136]. Employee and Management - The total number of employees at the end of the reporting period is 1,089, with 827 from the parent company and 262 from major subsidiaries[185]. - The company implements a performance-oriented compensation and assessment policy, rewarding employees based on individual work performance and professional capabilities[187]. - Employees enjoy benefits such as "five insurances and one fund," paid leave, and paid training, in accordance with national and local policies[187]. - The company has established special rewards for teams and individuals who make outstanding contributions, including overseas travel[187]. - The company has a strong management team with over 30 years of experience in investment and corporate management[160]. Environmental Responsibility - The company adheres to multiple environmental protection laws and regulations, including the Environmental Protection Law of the People's Republic of China and the Water Pollution Prevention and Control Law[200]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[200]. - The company actively engages in clean production initiatives as per the Clean Production Promotion Law of the People's Republic of China[200]. - The company monitors and manages solid waste pollution in accordance with the Solid Waste Pollution Prevention and Control Law[200].

Financial Performance - The company's revenue for Q1 2025 was CNY 217,836,836.34, representing a 1.17% increase compared to CNY 215,317,031.37 in the same period last year[5]. - Net profit attributable to shareholders increased by 136.47% to CNY 22,859,812.88 from CNY 9,667,223.23 year-on-year[5]. - The net profit after deducting non-recurring gains and losses rose by 168.15% to CNY 22,057,608.04 compared to CNY 8,225,848.56 in the previous year[5]. - Total operating revenue for the current period is $217.84 million, an increase from $215.32 million in the previous period, representing a growth of approximately 1.16%[19]. - Operating profit for the current period is $26.10 million, significantly up from $10.65 million in the previous period, marking an increase of approximately 144.61%[20]. - Net profit for the current period is $22.11 million, compared to $8.76 million in the previous period, reflecting a growth of around 151.36%[20]. - Basic and diluted earnings per share both increased to $0.04 from $0.02, a 100% increase[21]. Assets and Liabilities - The company's total assets increased by 3.45% to CNY 1,019,778,595.34 from CNY 985,730,497.97 at the end of the previous year[5]. - Current assets rose to CNY 585,761,028.62, up from CNY 543,118,402.76, indicating an increase of about 7.9%[15]. - Cash and cash equivalents increased to CNY 404,025,624.09 from CNY 344,774,257.71, representing a growth of approximately 17.2%[15]. - Total liabilities increased to CNY 278,652,215.28 from CNY 262,796,323.54, reflecting a growth of about 6.0%[17]. - The company's equity attributable to shareholders rose to CNY 720,228,118.28 from CNY 697,368,305.40, marking an increase of approximately 3.3%[17]. - The company's retained earnings increased to CNY 96,746,369.31 from CNY 73,886,556.43, representing a growth of about 31.0%[17]. - The company’s non-current liabilities decreased to CNY 19,630,708.08 from CNY 20,506,490.20, reflecting a decline of about 4.3%[17]. Cash Flow - Cash flow from operating activities decreased by 11.60% to CNY 48,166,664.21 compared to CNY 54,487,330.32 in the previous year[5]. - Cash flow from operating activities generated a net amount of $48.17 million, down from $54.49 million in the previous period, a decrease of about 11.56%[22]. - The company reported a significant increase in investment cash flow, with a net inflow of CNY 14,591,250.00 compared to a net outflow of CNY 119,485.74 in the same period last year, marking a 12,311.71% change[9]. - The company recorded a net cash inflow from investment activities of $14.59 million, compared to a net outflow of $119.49 thousand in the previous period[23]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 34,476, with the largest shareholder holding 50.27% of the shares[10]. Expenses - Research and development expenses increased to $10.27 million from $8.52 million, an increase of about 20.54%[20]. - The company reported a tax expense of $3.98 million, up from $2.01 million, indicating a rise of approximately 97.56%[20]. Other Financial Metrics - The weighted average return on equity improved to 3.23%, up from 1.19% in the same period last year, reflecting better profitability[5]. - The company's basic and diluted earnings per share both doubled to CNY 0.04 from CNY 0.02 in the previous year[5]. - The company experienced a 32.02% increase in prepaid accounts due to higher material procurement payments during the reporting period[9]. - Inventory decreased to CNY 98,562,497.96 from CNY 107,134,043.15, indicating a decline of approximately 8.5%[15]. - The company reported a decrease in contract liabilities to CNY 2,364,396.69 from CNY 6,850,350.20, indicating a decline of approximately 65.5%[16].

山东沃华医药科技股份有限公司 二〇二四年度财务报表 审 计 报 告 目 录 永拓会计师事务所（特殊普通合伙） 一、审计报告 二、财务报表 1．2024 年 12 月 31 日合并资产负债表及母公司资产负债表 2．2024 年度合并利润表及母公司利润表 3．2024 年度合并现金流量表及母公司现金流量表 4．2024 年度合并股东权益变动表及母公司股东权益变动 表 5．2024 年度财务报表附注 审计报告 永证审字（2025）第 110017 号 山东沃华医药科技股份有限公司全体股东： 一、审计意见 我们审计了山东沃华医药科技股份有限公司（以下简称"沃华医药"）合并 及母公司财冡报表，包括 2024 年 12 月 31 日的合并资产负债表和母公司资产负 债表，2024 年度的合并儩润表和母公司儩润表、合并现金流量表和母公司现金 流量表、合并股东权益变冨表和母公司股东权益变冨表以及相关财冡报表附注。 我们认为，后附的财冡报表在所有重大方面按照企业会计准儙的规定縖儶， 公允反映了沃华医药 2024 年 12 月 31 日的合并及母公司财冡状况以及 2024 年度 的合并及母公司经营成果和现金流量。 二、形成审计意见 ...

证券代码:002107 证券简称:沃华医药 m - 上东沃华医药科技股份有限公司 必独立董事提名人声明与承诺 提名人山东沃华医药科技股份有限公司董事会现就提名王跃生为山东沃华医药科技股份有限公司第8届董事会 独立董事候选人投表公开声明 被提名人已书面同意作为山东沃华医药科技股份有限公司第8届董事会独立董事候选 人(参见该独立董事候选人萨赐)。本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良魂录等情况后集出的,本提名人认为被提名人符合相关法律、行政法规、部门规章、规范性文件 和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求,具体声明并承诺如下事项: 一、被提名人已经通过山东沃华医药科技股份有限公司第7届董事会提名委员会或者独立董事专门会议资格审查,提 名人与被提名人不存在利害关系或者其他可能影响独立履职情形的密切关系。 √是 □否 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得担任公司董事的情形。 √是 □否 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所业务规则规定的独立董事任职资格和 条件。 √是 □否 四 ...

山东沃华医药科技股份有限公司 2025 年第一次临时股东会的 法律意见书 北京市星河律师事务所 法律意见书 北京市星河律师事务所 关 于 致：山东沃华医药科技股份有限公司 北京市星河律师事务所（以下简称本所）接受山东沃华医药科技股份有限公 司（以下简称贵公司）的委托，就贵公司召开 2025 年第一次临时股东会（以下 简称本次会议）的有关事宜，根据《中华人民共和国公司法》（以下简称《公司 法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上市公司股东 大会规则》（以下简称《大会规则》）及《山东沃华医药科技股份有限公司章程》 （以下简称《公司章程》）的有关规定，出具本法律意见书。 为出具本法律意见书，本所委派律师列席了本次会议。本所律师见证了本次 会议的召开全部过程，并对与本次会议召开有关的文件和事实进行了核查和验 证。 本所律师同意将本法律意见书作为贵公司本次股东会公告文件，随其他应当 公告的文件一起向公众披露，并依法对本所律师发表的法律意见承担法律责任。 本所律师根据《公司法》《大会规则》《公司章程》的有关规定，按照律师 行业公开的标准，道德规范和勤勉尽责的精神，现就本次会议出具法律意见如下： 一、关 ...

证券代码：002107 证券简称：沃华医药 公告编号：2025-006 山东沃华医药科技股份有限公司 2. 会议方式：本次股东会所采用的表决方式是现场表决与网络 投票相结合的方式； 3. 会议召开日期和时间： 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： （一）本次股东会无增加、否决或修改提案的情况。 （二）本次股东会不涉及变更前次股东会决议的情况。 一、会议召开和出席情况 （一）会议的召开情况 1. 会议召集人：公司董事会； 通过网络投票的股东 74 人，代表股份 1,384,747 股，占公司有表 决权股份总数的 0.2399％。 （二）会议的出席情况 通过现场和网络出席本次会议的股东及股东代理人 78 人，代表 股份 301,655,043 股，占公司有表决权股份总数的 52.2609％。 其中：通过现场投票的股东及股东代理人共 4 人，代表股份 300,270,296 股，占上市公司总股份的 52.0210％。 （1）现场会议：2025 年 2 月 10 日（星期一）14：00 （2）网络投票：通过深 ...

证券代码：002107 证券简称：沃华医药 公告编号：2025-008 山东沃华医药科技股份有限公司 二〇二五年二月十日 2 第八届监事会第一次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 山东沃华医药科技股份有限公司（以下简称公司）于 2025 年 2 月 10 日召开 2025 年第一次临时股东会，选举产生了第八届监事会成 员。为保证公司监事会顺利运行，经监事刘伯芳先生、王立先生、周 万辉先生、刘丽娟女士提议，全体监事同意后，豁免会议提前通知期 限，决定于 2025 年 2 月 10 日下午在公司会议室召开公司第八届监事 会第一次会议。会议应出席监事 5 名，实际出席会议监事 5 名。本次 会议由全体监事推举的监事印文军先生主持。会议的召开符合《公司 法》等相关法律法规及《公司章程》的规定。经与会监事认真审议， 本次会议通过了以下决议： 会议以 5 票同意，0 票反对，0 票弃权，审议通过了《关于选 举公司监事长的议案》。 选举印文军先生为公司监事长，任期同第八届监事会。 1 特此公告。 山东沃华医药科技股份有限公司监事会 ...

山东沃华医药科技股份有限公司 第八届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：002107 证券简称：沃华医药 公告编号：2025-007 山东沃华医药科技股份有限公司（以下简称公司）于 2025 年 2 月 10 日召开 2025 年第一次临时股东会，选举产生了第八届董事会成 员。为保证公司董事会顺利运行，经董事赵彩霞女士、张戈先生、王 炯先生、陈勇先生、高明芹女士提议，全体董事同意后，豁免会议提 前通知期限，决定于 2025 年 2 月 10 日下午在公司会议室召开公司第 八届董事会第一次会议。会议应出席董事 9 名，实际出席会议董事 9 名。本次会议由全体董事推举的董事赵丙贤先生主持。会议的召开符 合《公司法》等相关法律法规及《公司章程》的规定。经与会董事认 真审议，本次会议通过了以下决议： 一、会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关 于选举公司董事长的议案》。 选举赵丙贤先生为公司董事长，任期同第八届董事会。 二、会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关 于选举公司副董事长 ...

证券代码：002107 证券简称：沃华医药 公告编号：2025-003 山东沃华医药科技股份有限公司 二〇二五年一月二十三日 1 山东沃华医药科技股份有限公司 关于选举职工代表监事的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 公司第七届监事会任期即将届满，为了保证公司监事会的正常运 作，根据《公司法》《公司章程》的相关规定，公司于 2025 年 1 月 22 日在公司会议室召开了公司职工代表大会。经与会人员审议，通过 以下决议： 根据《公司法》《公司章程》《监事会议事规则》的有关规定， 一致同意选举周万辉先生、刘丽娟女士为公司第八届监事会职工代表 监事。将与公司股东会选举产生的 3 名非职工代表监事共同组成公司 第八届监事会，任期至第八届监事会任期届满时止。上述职工代表监 事符合《公司法》《公司章程》等法律法规有关监事任职的资格和条 件。公司本次职工代表大会选举的职工代表监事中无最近两年内曾担 任过公司董事或者高级管理人员的监事。简历详见附件。 特此公告。 周万辉先生，持有本公司股份9,500股,与持有公司5%以上股份的 股东、实际控制人、其他董事、 ...

证券代码：002107 证券简称：沃华医药 公告编号：2025-004 山东沃华医药科技股份有限公司 关于拟任独立董事的公告 截至本公告日，公司拟聘任的独立董事高明芹女士、王跃生先 生、俞俊利先生均已按照中国证监会《上市公司高级管理人员培训 工作指引》的规定取得独立董事资格证书。3 位拟聘任独立董事兼 任其他上市公司独立董事均不超过 3 家。 独立董事候选人的任职资格和独立性需经深圳证券交易所审核 无异议后方可提交公司 2025 年第一次临时股东会审议。 独立董事候选人简历详见公司同日发布的《第七届董事会第十 四次会议决议公告》。 山东沃华医药科技股份有限公司 二〇二五年一月二十三日 1 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 2025 年 1 月 23 日, 山东沃华医药科技股份有限公司（以下简 称公司）召开第七届董事会第十四次会议,审议通过了《关于提名公 司第八届董事会董事候选人的议案》。公司董事会提名高明芹女 士、王跃生先生、俞俊利先生 3 人为公司第八届董事会独立董事候 选人，任期三年，自股东会决议通过之日起计算。 ...